Following 6 h pretreatment with 25 μM costunolide, Bt-549 and MDA-MB-157 cells showed fewer microtentacles and reduced reattachment by electrical impedance monitoring. The assays support an in vitro attachment phenotype; they do not establish prevention of metastasis in animals or patients. [2]
AKT enrichment by costunolide beads and cellular signaling
Cell-based study · HCT-15, HCT-116 and DLD1 colorectal cancer cells and their lysates [1]
Costunolide-conjugated beads enriched AKT compared with unconjugated beads; MDM2 was not similarly recovered. Cellular treatment reduced the p-MDM2/MDM2 ratio. Figure 3e did not show a corresponding reduction in p-AKT/AKT. These assays do not establish a purified-enzyme IC50, binding affinity or unique target.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 2.5, 5 and 10 μM for cellular immunoblots; bead pull-down uses immobilized costunolide, not a soluble treatment dose.
- Exposure duration
- 24 h for Figure 3e cellular immunoblots.
- Method
- Cell treatment followed by the indicated assays.
- Vehicle
- DMSO is identified as the cellular control in Methods; final percentage is not specified.
- Co-treatment
- No combination treatment for selected cellular dose response; unconjugated Sepharose and input lysates provide pull-down controls.
- Reported limits
- No free-compound concentration or affinity is supplied for the immobilized-bead assay. Figure 3 caption does not specify a replicate count.
Methods and source locations
Compound reported in the paper: Costunolide; Compound label in the paper: CTD
Supports a costunolide-associated AKT interaction and signaling response in these models, without claims of selective direct kinase inhibition.
Methods: Reagents, Western blot assay, Pull-down assay using CNBr–costunolide-conjugated beads; Results Sec23; Figure 3c,e and caption.
AKT and MDM2 recovery from cell lysates: CTD-conjugated versus unconjugated Sepharose 4B pull-down, input lysates and immunoblotting. — Figure 3c; Results Sec23; Methods: Pull-down assay.
p-MDM2(Ser166)/MDM2 and p-AKT(Ser473)/AKT ratios: 24 h cellular treatment followed by phosphoprotein/total-protein immunoblot ratios; β-actin loading control. No bar heights digitized. — Figure 3e, displayed blots/ratio plots and caption.
Detyrosinated tubulin and short-term viability controls
Cell-based study · Bt-549 and MDA-MB-157 human breast carcinoma cells [2]
Costunolide reduced detyrosinated tubulin while overall α-tubulin networks remained visible. No PARP cleavage was detected and short-term viability was retained at the tested concentrations. Resveratrol inhibited the NF-κB reporter without reproducing the tubulin effect, supporting separation of these responses rather than proving a specific enzyme target.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5, 10 and 25 μM in Figure 1; 10 and 25 μM in Figure 2; 25 μM in Figure 3.
- Exposure duration
- 6 h for tubulin immunoblots, imaging and viability; reporter: 4 h drug exposure followed by 1 h TNF-α stimulation with drug present.
- Method
- Cell treatment followed by the indicated assays.
- Vehicle
- 0.1% DMSO.
- Co-treatment
- Costunolide single-agent tubulin and viability assays; TNF-α 100 ng/ml is the reporter stimulus. Parthenolide, resveratrol, colchicine and paclitaxel are separate comparator arms, not costunolide combinations.
- Reported limits
- Costunolide purity and independent stereochemical analytical validation are not specified in the acquired Methods.
Methods and source locations
Compound reported in the paper: Costunolide; Compound label in the paper: Cost
Short-term cellular tubulin phenotype; no direct tubulin-carboxypeptidase inhibition or clinical safety claim.
Methods: Cell culture and chemical compounds, Immunoblot, NF-κB activation, Cell viability, Indirect immunofluorescence; Figures 1–3 and captions; Results first three subsections.
Detyrosinated tubulin and PARP cleavage: Immunoblots normalized to α-tubulin; Figure 1 caption: N=3 Bt-549 and N=6 MDA-MB-157 experiments; mean densitometry ± SD. Caption significance symbols *P<0.05, **P<0.001, t-test. — Figure 1a and caption; first Results subsection. No exact effect sizes inferred.
Detyrosinated and overall α-tubulin filament appearance: Indirect immunofluorescence after 6 h, vehicle and separate drug controls. — Figure 3a–b and caption; Methods: Indirect immunofluorescence.
Short-term viability and NF-κB reporter dissociation control: Six-hour metabolic viability assay; stimulated reporter with separate resveratrol comparator. Methods report mean ± SD of triplicate samples; this does not specify biological replicates. — Figure 2a–b and caption; Figure 1a for resveratrol tubulin control; corresponding Methods and Results.
Microtentacles and tumor-cell reattachment
Cell-based study · Suspended and replated Bt-549 and MDA-MB-157 human breast carcinoma cells [2]
Costunolide reduced microtentacle frequency and subsequent attachment measured by electrical impedance. Resveratrol and paclitaxel did not significantly reduce microtentacle frequency and did not reproduce costunolide’s attachment inhibition. These are cell-based functional endpoints, not an animal metastasis test.
Literature-Reported Treatment Conditions
- Treatment concentration
- 25 μM costunolide.
- Exposure duration
- 6 h pretreatment; drug remained present during suspension scoring and reattachment. Scoring at 15–30 min after detachment; impedance monitored for 3.5 h.
- Method
- Cell treatment followed by the indicated assays.
- Vehicle
- 0.1% DMSO.
- Co-treatment
- Single-agent costunolide versus vehicle and separate comparator drugs.
- Reported limits
- No exact percentage reduction or attachment rate is extracted from plotted curves.
Methods and source locations
Compound reported in the paper: Costunolide; Compound label in the paper: Cost
Supports decreased microtentacle frequency and in vitro reattachment in two breast cancer cell lines.
Methods: Live cell imaging and microtentacle scoring, Cell-electrode impedance attachment assay; Figures 4–5 and captions; final two Results subsections.
Frequency of cells with microtentacles: Six independent experiments; at least 100 cells scored blindly per experiment; Figure 4 caption uses *P<0.05, **P<0.001, t-test. — Figure 4a–b and caption; Results: Parthenolide and costunolide decrease microtentacle frequency.
Cell-substratum attachment: Real-time xCELLigence monitoring; representative curve is mean ± SD of triplicate wells; three independent experiments reported. — Figure 5 and caption; Methods: Cell-electrode impedance attachment assay. No exact curve values extracted.
JNK activation after costunolide exposure
Cell-based study · U937 human promonocytic leukemia cells [3]
Costunolide increased JNK phosphorylation and lysate-derived JNK activity. The Results report mild ERK1/2 activation and no p38 activation, qualifying the broader abstract wording. This experiment measures a cellular response, not direct binding of costunolide to JNK.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM.
- Exposure duration
- 15–120 min for phosphoprotein time course; 30 and 60 min increases in kinase activity.
- Method
- Cell treatment followed by the indicated assays.
- Vehicle
- Untreated/time-zero controls; treatment vehicle is not specified in the acquired cellular methods.
- Co-treatment
- Costunolide alone in the selected time course.
- Reported limits
- No numerical fold changes are extracted from bands.
Methods and source locations
Compound reported in the paper: Costunolide; Compound label in the paper: Costunolide
U937 cellular JNK response only; no animal efficacy or dosing claim.
pp.1803–1805: Materials, cellular and kinase methods, Results first subsection, Figure 1a–b and caption.
JNK phosphorylation and kinase activity: Phospho/total MAPK immunoblots and lysate-derived c-Jun phosphorylation assay. Figure 1 is representative of three separate experiments. — p.1804 Results first subsection; p.1805 Figure 1a–b/caption; p.1804 In Vitro Kinases Assay.